S
Solta Medical
Solta Medical - Medical Aesthetic Devices > Splash
About Solta Medical
Solta Medical operates as a prominent entity in the medical aesthetics market, designing, developing, manufacturing, and marketing energy-based medical device systems. The company was originally founded as Thermage, Inc. in 1996 by Dr. Edward W. Knowlton, a cosmetic, plastic, and reconstructive surgery specialist who invented the Thermage ThermaCool™ device. Dr. Knowlton, a graduate of Washington University School of Medicine, guided the company with a vision to innovate aesthetic procedures beyond traditional invasive treatments.
The company's business model centers on selling these capital equipment systems to medical professionals and generating recurring revenue from the sale of high-margin disposable components required for each procedure. Its client base primarily consists of dermatologists, plastic surgeons, and other aesthetic practitioners. Solta's revenue stream is diversified through a tiered customer loyalty program, PURE, which offers instant savings and benefits based on annual purchase volumes of consumables.
Solta's product portfolio addresses a wide array of aesthetic concerns. The flagship Thermage® system utilizes radiofrequency technology for non-invasive skin tightening. The Fraxel® family of lasers, which became part of the company through a merger with Reliant Technologies, offers fractional skin resurfacing to treat wrinkles, scars, and sun damage. Other key products include the Clear + Brilliant® laser system for preventative skin care, and VASER® ultrasonic systems for body contouring and sculpting. Collectively, these brands cover applications from skin rejuvenation and tightening to acne reduction and body contouring.
Throughout its history, Solta has experienced significant corporate changes. It became Solta Medical after integrating with Reliant Technologies. In December 2013, following a period of financial difficulty, the company was acquired by Valeant Pharmaceuticals, now Bausch Health Companies Inc., for approximately $250 million. This acquisition integrated Solta into a broader portfolio of healthcare products. Bausch Health later announced plans for an initial public offering (IPO) for Solta Medical to unlock its value and pay down debt, though these plans were suspended in June 2022 due to market conditions. Solta now operates as a subsidiary of Bausch Health.
Source: Dealroom company dataNews
Open roles
Solta Medical in the Bothell ecosystem
The Solta Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Longitude Capital
Great Point Partners
Series B and later1 investor entered at this stage
CRG
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Solta Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Solta Medical on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

